We are live on ! Find out more
ACM

AIGH Capital Management Portfolio holdings

AUM $1.59B
1-Year Est. Return 855.46%
This Fund
S&P 500
This Quarter Est. Return
+27.64%
1 Year Est. Return
+855.46%
3 Year Est. Return
+3,007.26%
5 Year Est. Return
+4,204.76%
10 Year Est. Return
AUM
$475M
AUM Growth
+$229M
Cap. Flow
+$255M
Cap. Flow %
53.55%
Top 10 Hldgs %
60.84%
Holding
72
New
25
Increased
12
Reduced
4
Closed
24

Top Sells

Rank Stock Value
1
BLBD icon
Blue Bird Corp
BLBD
+$15M
2
CLDR
Cloudera, Inc.
CLDR
+$13.9M
3
FFIV icon
F5
FFIV
+$13.2M
4
COHR
Coherent Inc
COHR
+$11.8M
5
BFX
BowFlex Inc.
BFX
+$11.8M

Sector Composition

Rank Sector Weight
1 Technology 26.15%
2 Healthcare 20.56%
3 Industrials 2.81%
4 Consumer Discretionary 1.6%
5 Consumer Staples 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INFI
26
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.33M 1.12%
+1,650,256
New +$5.51M
PRTK
27
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.29M 1.11%
749,608
ALIM
28
DELISTED
Alimera Sciences
ALIM
$4.82M 1.01%
501,025
YTEN
29
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$4.76M 1%
+15,833
New +$5.36M
MYO icon
30
Myomo
MYO
$57M
$4.57M 0.96%
356,925
-76,644
-18% -$928K
TLND
31
DELISTED
Talend S.A. American Depositary Shares
TLND
$4.19M 0.88%
+65,800
New +$3.42M
PCSA icon
32
Processa Pharmaceuticals
PCSA
$7.03M
$4.01M 0.84%
+774
New +$3.61M
MDNA
33
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$3.43M 0.72%
+840,000
New +$3.42M
ANVS icon
34
Annovis Bio
ANVS
$79.1M
$3.1M 0.65%
117,256
-346,541
-75% -$7.41M
NUWE icon
35
Nuwellis
NUWE
$536K
0
NVNO
36
enVVeno Medical
NVNO
$7.44M
$2.85M 0.6%
+12,245
New +$3.41M
DCOY
37
Decoy Therapeutics
DCOY
$2.09M
$2.66M 0.56%
50
+8
+19% +$459K
EVOK
38
DELISTED
Evoke Pharma
EVOK
$2.62M 0.55%
+9,952
New +$3.98M
ARDS
39
DELISTED
Aridis Pharmaceuticals Inc. Common Stock
ARDS
$2.5M 0.52%
423,357
+76,341
+22% +$516K
EXFO
40
DELISTED
EXFO INC.
EXFO
$2.23M 0.47%
+522,492
New +$2.09M
DAIO icon
41
Data I/O
DAIO
$30.8M
$2.05M 0.43%
378,310
+179,465
+90% +$957K
HSDT icon
42
Solana Company
HSDT
$99.3M
$1.82M 0.38%
+3
New +$1.66M
HTGM
43
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$1.27M 0.27%
+19,333
New +$1.47M
GANX icon
44
Gain Therapeutics
GANX
$77.6M
$982K 0.21%
+65,809
New +$864K
BLIN icon
45
Bridgeline Digital
BLIN
$14.7M
$512K 0.11%
+177,419
New +$569K
HYPD
46
Hyperion DeFi Inc
HYPD
$40.9M
$408K 0.09%
+998
New +$505K
CYTH
47
DELISTED
Cyclo Therapeutics, Inc. Common Stock
CYTH
$141K 0.03%
17,235
-332,765
-95% -$2.77M
GRI
48
GRI Bio
GRI
$2.64M
0
BLBD icon
49
Blue Bird Corp
BLBD
$2.14B
-819,360
Closed -$15M
CPRX
50
DELISTED
Catalyst Pharmaceutical
CPRX
-1,350,554
Closed -$4.51M

Similar funds

AIGH Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, AIGH Capital Management held 72 positions worth $475M, up 93% from $246M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

AIGH Capital Management deployed $255M of net new capital in Q1 2021, opening 25 new positions and adding to 12 existing holdings. Its largest new stake was Franklin Wireless: 780,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 38% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Avaya Holdings Corp. Common Stock, an estimated $8.02M trimmed.

  • AIGH Capital Management's largest Q1 2021 buy was Franklin Wireless: 780,000 shares worth $13.9M.
  • AIGH Capital Management added most to THERATECHNOLOGIES INC COM in Q1 2021, an estimated $11.6M increase.
  • AIGH Capital Management's biggest Q1 2021 reduction was Avaya Holdings Corp. Common Stock, cutting an estimated $8.02M.
  • AIGH Capital Management fully exited Blue Bird Corp in Q1 2021, selling an estimated $15M.
  • AIGH Capital Management's ten largest holdings make up 61% of its $475M portfolio in Q1 2021.
  • AIGH Capital Management opened 25 new positions and closed 24 in Q1 2021.
  • AIGH Capital Management's portfolio value rose 93% quarter-over-quarter to $475M.

Based on AIGH Capital Management's 13F filing for Q1 2021, filed 13 May 2021.